Lin Han, Chen Lu, Huang Ruoyao, Xue Shufang, Sun Gaoyuan, Wang Chengyi, Shen Shuhong, Zhang Hui, Zheng Yongzhi
Department of Haematology & Oncology, Fujian Children's Hospital.
Department of Haematology & Oncology, Fujian Branch of Shanghai Children's Medical Center, Fuzhou.
Pharmacogenet Genomics. 2025 Apr 1;35(3):110-115. doi: 10.1097/FPC.0000000000000554. Epub 2025 Feb 25.
Based on driver mutations and gene expression profiles, the International Consensus Classification currently divided the entity 'Philadelphia chromosome-positive (Ph + ) B-cell precursor acute lymphoblastic leukemia (ALL)' into two subtypes: lymphoid-only and multilineage involvement (Ph + ALL-L and -M, respectively). The similar biological characteristics of Ph-like ALL and Ph + ALL drove us to assume that Ph-like ALL-M subtypes exist. This report presents two pediatric ALL cases (one Ph + and one Ph-like) with minimal residual disease negativity established by multicolor flow cytometry but persistent transcript detection by quantitative PCR (qPCR) even after second-line treatment with tyrosine kinase inhibitors combined with blinatumomab immunotherapy. Using droplet digital PCR, BCR::ABL1 or TPM3::PDGFRB transcripts were identified in CD19 + cells as well as in non-CD19 + cells, suggesting the presence of a Ph + or Ph-like ALL-M subtype originating from hematopoietic stem cells. This report provides information for better characterization, diagnosis, and treatment of these ALL subtypes.
基于驱动基因突变和基因表达谱,国际共识分类目前将“费城染色体阳性(Ph +)B细胞前体急性淋巴细胞白血病(ALL)”实体分为两个亚型:仅淋巴细胞型和多谱系受累型(分别为Ph + ALL-L和-Ph + ALL-M)。Ph样ALL和Ph + ALL的相似生物学特征促使我们推测存在Ph样ALL-M亚型。本报告介绍了两例儿童ALL病例(一例Ph +和一例Ph样),通过多色流式细胞术确定微小残留病为阴性,但即使在酪氨酸激酶抑制剂联合blinatumomab免疫疗法进行二线治疗后,定量PCR(qPCR)仍能持续检测到转录本。使用液滴数字PCR,在CD19 +细胞以及非CD19 +细胞中鉴定出BCR::ABL1或TPM3::PDGFRB转录本,提示存在源自造血干细胞的Ph +或Ph样ALL-M亚型。本报告为更好地表征、诊断和治疗这些ALL亚型提供了信息。